These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 29976833)
41. Cortical Gray Matter MR Imaging in Multiple Sclerosis. Calabrese M; Castellaro M Neuroimaging Clin N Am; 2017 May; 27(2):301-312. PubMed ID: 28391788 [TBL] [Abstract][Full Text] [Related]
42. White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. Fuchs TA; Dwyer MG; Kuceyeski A; Choudhery S; Carolus K; Li X; Mallory M; Weinstock-Guttman B; Jakimovski D; Ramasamy D; Zivadinov R; Benedict RHB Hum Brain Mapp; 2018 Sep; 39(9):3682-3690. PubMed ID: 29740964 [TBL] [Abstract][Full Text] [Related]
43. Differential white and gray matter damage in highly active multiple sclerosis: A prospective cohort study. Pappolla A; Sánchez F; Caro F; Miguez J; Patrucco L; Cristiano E; Rojas JI J Clin Neurosci; 2020 Apr; 74():65-68. PubMed ID: 32001112 [TBL] [Abstract][Full Text] [Related]
44. The role of global and regional gray matter volume decrease in multiple sclerosis. Grothe M; Lotze M; Langner S; Dressel A J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570 [TBL] [Abstract][Full Text] [Related]
45. Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course. Cortese R; Battaglini M; Parodi F; Stromillo ML; Portaccio E; Razzolini L; Giorgio A; Sormani MP; Amato MP; De Stefano N Mult Scler; 2022 Jan; 28(1):154-159. PubMed ID: 34100326 [TBL] [Abstract][Full Text] [Related]
48. Accurate GM atrophy quantification in MS using lesion-filling with co-registered 2D lesion masks. Popescu V; Ran NC; Barkhof F; Chard DT; Wheeler-Kingshott CA; Vrenken H Neuroimage Clin; 2014; 4():366-73. PubMed ID: 24567908 [TBL] [Abstract][Full Text] [Related]
49. Evaluating the effects of white matter multiple sclerosis lesions on the volume estimation of 6 brain tissue segmentation methods. Valverde S; Oliver A; Díez Y; Cabezas M; Vilanova JC; Ramió-Torrentà L; Rovira À; Lladó X AJNR Am J Neuroradiol; 2015 Jun; 36(6):1109-15. PubMed ID: 25678478 [TBL] [Abstract][Full Text] [Related]
50. Gray- and white-matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging. Raz E; Cercignani M; Sbardella E; Totaro P; Pozzilli C; Bozzali M; Pantano P Radiology; 2010 Nov; 257(2):448-54. PubMed ID: 20858849 [TBL] [Abstract][Full Text] [Related]
51. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis. Gaetano L; Häring DA; Radue EW; Mueller-Lenke N; Thakur A; Tomic D; Kappos L; Sprenger T Neurology; 2018 Apr; 90(15):e1324-e1332. PubMed ID: 29540589 [TBL] [Abstract][Full Text] [Related]
52. Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis. Roostaei T; Sadaghiani S; Mashhadi R; Falahatian M; Mohamadi E; Javadian N; Nazeri A; Doosti R; Naser Moghadasi A; Owji M; Hashemi Taheri AP; Shakouri Rad A; Azimi A; Voineskos AN; Nazeri A; Sahraian MA Mult Scler; 2019 Apr; 25(4):532-540. PubMed ID: 29485352 [TBL] [Abstract][Full Text] [Related]
53. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. Koskimäki F; Bernard J; Yong J; Arndt N; Carroll T; Lee SK; Reder AT; Javed A PLoS One; 2018; 13(12):e0209326. PubMed ID: 30576361 [TBL] [Abstract][Full Text] [Related]